Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026
Same author

Cerebellar magnetization transfer ratio and its relationship to clinical outcomes in radiologically isolated syndrome and multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Increased PET <sup>11</sup>C-PBR28 binding in multiple sclerosis normal-appearing white matter correlates with MRI measures of myelin loss.

Multiple sclerosis and related disorders·2026

Related Experiment Video

Updated: Jun 5, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Escalating immunotherapy of multiple sclerosis.

Peter Rieckmann1, Anthony Traboulsee, Virginia Devonshire

  • 1Director, Multiple Sclerosis Program Division of Neurology, University of British Columbia, Vancouver, Canada prieckmann@brain.ubc.ca.

Therapeutic Advances in Neurological Disorders
|December 25, 2010
PubMed
Summary

Effective escalating treatments for active multiple sclerosis (MS) are urgently needed as current therapies offer limited efficacy. Further research is essential to evaluate intensified immunosuppression strategies for MS patients with suboptimal responses.

Keywords:
clinically isolated syndromesglatiramer acetateimmunotherapyinterferon-betamultiple sclerosisnatalizumab

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: Jun 5, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Inflammatory Diseases

Background:

  • Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease.
  • Available disease-modifying treatments (DMTs) for relapsing MS, including interferon-beta and glatiramer acetate, show partial effectiveness.
  • Early treatment initiation, even in clinically isolated syndromes (CIS), is supported by trial data.

Purpose of the Study:

  • To review current and potential escalating immunotherapy strategies for treatment-refractory active MS.
  • To highlight the urgent need for effective treatments to prevent irreversible neurological disability.
  • To advocate for innovative study designs to rigorously evaluate intensified immunosuppression in MS.

Main Methods:

  • Review of existing literature on MS treatments.
  • Analysis of current therapeutic options for patients with suboptimal response to basic therapy.
  • Discussion of treatment escalation strategies including combination therapies, cytotoxic drugs, stem cell transplantation, and natalizumab.

Main Results:

  • Currently available basic therapies for MS are only partially effective, leading to continued relapses and progression in some patients.
  • Escalation strategies like combination therapies, cytotoxic drugs, stem cell transplantation, and natalizumab are used but lack robust evaluation in phase III trials for patients failing basic therapy.
  • The decision to escalate immunotherapy is based on limited evidence.

Conclusions:

  • There is an urgent need for effective escalating immunotherapy strategies for active MS.
  • Current escalation options have not been rigorously evaluated in large randomized controlled trials for patients with suboptimal treatment response.
  • Innovative study designs are required to better assess the efficacy and safety of intensified immunosuppression in MS.